乳腺癌的靶向治疗  

Targeted therapy for breast cancer

作　　者：刘战涛 宋艳秋[2] Liu Zhantao;Song Yanqiu(Department of Medical Oncology,Xiangyang Central Hospital/Affiliated Hospital of Hubei University of Arts and Science,Xiangyang 441000,China;Department of Medical Oncology,First Hospital of Jilin University,Changchun 130021,China)

机构地区：[1]湖北文理学院附属医院/襄阳市中心医院肿瘤内科,湖北襄阳441000 [2]吉林大学第一医院肿瘤内科,长春130021

出　　处：《中华乳腺病杂志（电子版）》2021年第6期329-336,共8页Chinese Journal of Breast Disease(Electronic Edition)

基　　金：吉林省自然科学基金资助项目(20160101028JC)。

摘　　要：靶向治疗是一种低毒、高选择性的治疗模式。曲妥珠单克隆抗体作为乳腺癌靶向治疗史上最经典的药物,已使成千上万乳腺癌患者受益。随着学者们对肿瘤发生、发展及转移机制的不断探索,靶向治疗药物的研究和应用已取得了突破性进展,为改善乳腺癌患者的生存状况提供了新的治疗策略和途径。笔者就目前不同分子分型乳腺癌的潜在靶点及靶向治疗药物研究进行归纳、总结。Targeted therapy is a treatment mode with low toxicity and high selectivity.Trastuzumab,as one of the“classic”drugs in the history of targeted therapy for breast cancer,has benefited thousands of breast cancer patients.With the continuous exploration on the mechanism of tumorigenesis,development and metastasis,breakthroughs have been made in the research and application of targeted drugs,which provides a new therapeutic strategy for the improvement of patient survival.In this paper,we summarized the research progress of potential targets and targeted drugs for breast cancer patients.

关 键 词：乳腺肿瘤 分子靶向治疗 药物疗法 

分 类 号：R737.9[医药卫生—肿瘤]